Kunal S. Taskar

2.1k total citations · 1 hit paper
30 papers, 1.4k citations indexed

About

Kunal S. Taskar is a scholar working on Oncology, Pediatrics, Perinatology and Child Health and Pharmacology. According to data from OpenAlex, Kunal S. Taskar has authored 30 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Oncology, 18 papers in Pediatrics, Perinatology and Child Health and 10 papers in Pharmacology. Recurrent topics in Kunal S. Taskar's work include Drug Transport and Resistance Mechanisms (17 papers), Pharmacological Effects and Toxicity Studies (17 papers) and Pharmacogenetics and Drug Metabolism (9 papers). Kunal S. Taskar is often cited by papers focused on Drug Transport and Resistance Mechanisms (17 papers), Pharmacological Effects and Toxicity Studies (17 papers) and Pharmacogenetics and Drug Metabolism (9 papers). Kunal S. Taskar collaborates with scholars based in United Kingdom, United States and Japan. Kunal S. Taskar's co-authors include Patricia S. Steeg, Helen R. Thorsheim, Quentin R. Smith, Vinay Rudraraju, Paul R. Lockman, Diane Palmieri, Rajendar K. Mittapalli, Julie A. Gaasch, Brunilde Gril and Suyun Huang and has published in prestigious journals such as SHILAP Revista de lepidopterología, Clinical Cancer Research and Pharmaceutical Research.

In The Last Decade

Kunal S. Taskar

29 papers receiving 1.4k citations

Hit Papers

Heterogeneous Blood–Tumor Barrier Permeability Determines... 2010 2026 2015 2020 2010 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Heterogeneous Blood–Tumor Barrier Permeability Determines Drug Efficacy in Experimental Brain Metastases of Breast Cancer
    2010 524 citations Paul R. Lockman, Rajendar K. Mittapalli et al. Clinical Cancer Research profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Kunal S. Taskar United Kingdom 15 790 462 303 280 236 30 1.4k
György Várady Hungary 23 989 1.3× 154 0.3× 804 2.7× 135 0.5× 94 0.4× 73 1.7k
Maria Palmisano United States 23 385 0.5× 150 0.3× 503 1.7× 135 0.5× 102 0.4× 85 1.5k
Larry J. Schaaf United States 26 1.5k 1.9× 537 1.2× 1.4k 4.6× 460 1.6× 108 0.5× 89 2.8k
Ken Ohmine Japan 21 528 0.7× 73 0.2× 605 2.0× 210 0.8× 70 0.3× 82 1.4k
Masanori Miwa Japan 14 2.0k 2.5× 346 0.7× 999 3.3× 55 0.2× 144 0.6× 33 3.0k
Roxanne C. Jewell United States 22 1.1k 1.4× 82 0.2× 608 2.0× 259 0.9× 138 0.6× 59 1.8k
Mohamed Elmeliegy United States 16 583 0.7× 289 0.6× 304 1.0× 105 0.4× 86 0.4× 52 944
Mario D’Andrea Italy 18 1.2k 1.5× 231 0.5× 857 2.8× 33 0.1× 160 0.7× 54 1.8k
Alice A. Gibson United States 23 790 1.0× 158 0.3× 391 1.3× 101 0.4× 213 0.9× 46 1.4k

Countries citing papers authored by Kunal S. Taskar

Since Specialization
Citations

This map shows the geographic impact of Kunal S. Taskar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kunal S. Taskar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kunal S. Taskar more than expected).

Fields of papers citing papers by Kunal S. Taskar

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kunal S. Taskar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kunal S. Taskar. The network helps show where Kunal S. Taskar may publish in the future.

Co-authorship network of co-authors of Kunal S. Taskar

This figure shows the co-authorship network connecting the top 25 collaborators of Kunal S. Taskar. A scholar is included among the top collaborators of Kunal S. Taskar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kunal S. Taskar. Kunal S. Taskar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Taskar, Kunal S., Kenta Yoshida, Tadayuki Takashima, et al.. (2025). Bridging in vitro and clinical data: Experimental insights into the IC50 variability of dolutegravir as an organic cation transporter 2 inhibitor. Drug Metabolism and Disposition. 53(6). 100087–100087. 1 indexed citations
2.
Stamatopoulos, Konstantinos, et al.. (2025). Physiologically Based Pharmacokinetic Modeling of Phosphate Prodrugs─Case Studies: Fostemsavir and Fostamatinib. Molecular Pharmaceutics. 22(4). 2168–2181. 1 indexed citations
3.
4.
Galluppi, Gerald R., Malidi Ahamadi, Nageshwar Budha, et al.. (2024). Considerations for Industry—Preparing for the FDA Model‐Informed Drug Development (MIDD) Paired Meeting Program. Clinical Pharmacology & Therapeutics. 116(2). 282–288. 6 indexed citations
5.
Salem, Farzaneh, Dung N. Nguyen, Mark Bush, et al.. (2024). Development of a physiologically based pharmacokinetic model of fostemsavir and its pivotal application to support dosing in pregnancy. CPT Pharmacometrics & Systems Pharmacology. 13(11). 1881–1892. 4 indexed citations
6.
Taskar, Kunal S., Maciej J. Zamek‐Gliszczynski, Kenta Yoshida, et al.. (2024). Effects of Cimetidine and Dolutegravir on the Endogenous Drug–Drug Interaction Biomarkers for Organic Cation Transporter 2 and Multidrug and Toxin Extrusion Protein 1 in Healthy Volunteers. Clinical Pharmacology & Therapeutics. 117(2). 523–533. 7 indexed citations
7.
Lewis, Gareth, et al.. (2023). Physiologically‐based pharmacokinetic modeling of prominent oral contraceptive agents and applications in drug–drug interactions. CPT Pharmacometrics & Systems Pharmacology. 13(4). 563–575. 5 indexed citations
8.
Salem, Farzaneh, et al.. (2023). Physiologically based pharmacokinetic modeling for development and applications of a virtual celiac disease population using felodipine as a model drug. CPT Pharmacometrics & Systems Pharmacology. 12(6). 808–820. 4 indexed citations
9.
Chothe, Paresh P., Vikram Arya, Bhagwat Prasad, Diane Ramsden, & Kunal S. Taskar. (2023). Innovations, Opportunities, and Challenges for Predicting Alteration in Drug-Metabolizing Enzyme and Transporter Activity in Specific Populations. Drug Metabolism and Disposition. 51(12). 1547–1550. 3 indexed citations
10.
Mochizuki, Tatsuki, Yasunori Aoki, Takashi Yoshikado, et al.. (2022). Physiologically‐based pharmacokinetic model‐based translation of OATP1B‐mediated drug–drug interactions from coproporphyrin I to probe drugs. Clinical and Translational Science. 15(6). 1519–1531. 24 indexed citations
11.
Taskar, Kunal S., Xinning Yang, Sibylle Neuhoff, et al.. (2022). Clinical Relevance of Hepatic and Renal P‐gp/BCRP Inhibition of Drugs: An International Transporter Consortium Perspective. Clinical Pharmacology & Therapeutics. 112(3). 573–592. 23 indexed citations
12.
Taskar, Kunal S., et al.. (2021). Physiologically-based Pharmacokinetic (PBPK) Modelling of Transporter Mediated Drug Absorption, Clearance and Drug-drug Interactions. Current Drug Metabolism. 22(7). 523–531. 16 indexed citations
13.
Zamek‐Gliszczynski, Maciej J., Mitesh Patel, Xinning Yang, et al.. (2020). Intestinal P‐gp and Putative Hepatic OATP1B Induction: International Transporter Consortium Perspective on Drug Development Implications. Clinical Pharmacology & Therapeutics. 109(1). 55–64. 39 indexed citations
14.
Patel, Aarti, Robert Wilson, Andrew W. Harrell, et al.. (2020). Drug Interactions for Low-Dose Inhaled Nemiralisib: A Case Study Integrating Modeling, In Vitro, and Clinical Investigations. Drug Metabolism and Disposition. 48(4). 307–316. 6 indexed citations
15.
Zamek‐Gliszczynski, Maciej J., et al.. (2019). Clinical Extrapolation of the Effects of Dolutegravir and Other HIV Integrase Inhibitors on Folate Transport Pathways. Drug Metabolism and Disposition. 47(8). 890–898. 17 indexed citations
16.
Samala, Ramakrishna, Helen R. Thorsheim, Kunal S. Taskar, et al.. (2016). Vinorelbine Delivery and Efficacy in the MDA-MB-231BR Preclinical Model of Brain Metastases of Breast Cancer. Pharmaceutical Research. 33(12). 2904–2919. 23 indexed citations
17.
Patel, Mitesh, Kunal S. Taskar, & Maciej J. Zamek‐Gliszczynski. (2016). Importance of Hepatic Transporters in Clinical Disposition of Drugs and Their Metabolites. The Journal of Clinical Pharmacology. 56(S7). S23–39. 81 indexed citations
18.
Taskar, Kunal S., Vinay Rudraraju, Rajendar K. Mittapalli, et al.. (2011). Lapatinib Distribution in HER2 Overexpressing Experimental Brain Metastases of Breast Cancer. Pharmaceutical Research. 29(3). 770–781. 160 indexed citations
19.
Lockman, Paul R., Rajendar K. Mittapalli, Kunal S. Taskar, et al.. (2010). Heterogeneous Blood–Tumor Barrier Permeability Determines Drug Efficacy in Experimental Brain Metastases of Breast Cancer. Clinical Cancer Research. 16(23). 5664–5678. 524 indexed citations breakdown →
20.
Thomas, Fancy, Kunal S. Taskar, Vinay Rudraraju, et al.. (2009). Uptake of ANG1005, A Novel Paclitaxel Derivative, Through the Blood-Brain Barrier into Brain and Experimental Brain Metastases of Breast Cancer. Pharmaceutical Research. 26(11). 2486–2494. 173 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by György Várady Breakdown of academic impact, for papers by Maria Palmisano Breakdown of academic impact, for papers by Larry J. Schaaf Breakdown of academic impact, for papers by Ken Ohmine Breakdown of academic impact, for papers by Masanori Miwa Breakdown of academic impact, for papers by Roxanne C. Jewell Breakdown of academic impact, for papers by Mohamed Elmeliegy Breakdown of academic impact, for papers by Mario D’Andrea Breakdown of academic impact, for papers by Alice A. Gibson
Rankless by CCL
2026